Systemic lupus erythematosus commonly presents as a rash. The rashes are caused by inflammation from the immune system fighting the body. Systemic lupus erythematosus, more commonly known as lupus, ...
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from ...
The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 weeks, according to data published in Arthritis & Rheumatology.“As a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results